Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The roll-forward of activity related to our goodwill was as follows (in thousands):



	Year Ended
	2013		2012
Balance, beginning of period	$	131,320	$	58,053
Additions	3,268		69,398
Goodwill adjustments	1,564		3,869
Balance, end of period	$	136,152	$	131,320

Additions to goodwill represent goodwill from an acquisition made during the period. Adjustments to goodwill include translation adjustments resulting from a portion of our goodwill being recorded on the books of our foreign subsidiaries as well as an adjustment related to the finalization of the purchase price allocation of the acquisition of ASPEX Corporation in 2012.

Acquisition of nanoTechnology Systems Pty. Ltd.

On August 9, 2013, we acquired 100% of the outstanding shares of nanoTechnology Systems Pty. Ltd. (NTS) of Melbourne, Australia, which had operated as our exclusive distributor in Australia and New Zealand for approximately 10 years. The total purchase price of the acquisition was approximately $3.6 million.

No pro forma or disclosure has been provided for this acquisition as it is insignificant.

Other Intangible Assets

Patents, trademarks and other are amortized under the straight-line method over their estimated useful lives of 2 to 15 years. Customer relationships are amortized under the straight-line method over their estimated useful lives of 5 to 10 years. Developed technology is amortized under the straight-line method over the estimated useful life of the related technology, which ranges from 5.5 to 10 years. Note issuance costs were amortized over the life of the related debt, which was 7 years.

Asset Impairment Charges

As part of our annual impairment test of long-lived intangible assets performed in the fourth quarter of 2011, we determined that the carrying value of certain intellectual property was not recoverable as we no longer intend to use the associated technology. As a result, we recorded an impairment charge of $1.4 million to write-off the remaining net book value of the intellectual property. The impairment loss is recorded within the selling, general and administrative expense line of our Consolidated Statements of Operations and is reported under the Science Group. There were no impairment charges recorded during 2013 or 2012.

The gross amount of our other intangible assets and the related accumulated amortization were as follows (in thousands):



	December 31,
	2013			2012
Patents, trademarks and other	$	24,327		$	22,047
Accumulated amortization	(9,296		)	(5,743		)
Net patents, trademarks and other	15,031			16,304
Customer relationships	21,650			20,305
Accumulated amortization	(3,547		)	(1,171		)
Net customer relationships	18,103			19,134
Developed technology	18,161			17,686
Accumulated amortization	(4,098		)	(1,771		)
Net developed technology	14,063			15,915
Note issuance costs	2,445			2,445
Accumulated amortization	(2,445		)	(2,299		)
Net note issuance costs	—			146
Total intangible assets included in other long-term assets	$	47,197		$	51,499

Amortization expense was as follows (in thousands):



	Year Ended
	2013		2012		2011
Patents, trademarks and other	$	3,553	$	1,993	$	1,342
Customer relationships	2,376		1,168		3
Developed technology	2,327		1,716		55
Note issuance costs	146		350		350
Total amortization expense	$	8,402	$	5,227	$	1,750

Expected amortization, without consideration for foreign currency effects, is as follows over the next five years and thereafter (in thousands):



	Patents, Trademarks and Other		Customer Relationships		Developed Technology		Total
2014	$	3,234	$	2,420	$	2,291	$	7,945
2015	3,019		2,420		2,291		7,730
2016	2,757		2,420		2,291		7,468
2017	2,214		2,072		2,010		6,296
2018	1,646		1,988		1,847		5,481
Thereafter	2,161		6,783		3,333		12,277
Total future amortization expense	$	15,031	$	18,103	$	14,063	$	47,197

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details